The main difference concerns the storage conditions.
And two. Since yesterday, France has a new weapon against Covid-19 with the delivery of the first batches of Moderna’s vaccine, a week after its validation by the European Medicines Agency (EMA) and barely more than fifteen days after the release of the Pfizer / BioNTech Comirnaty. More than 50,000 doses will be sent to the Grand Est, Auvergne-Rhône-Alpes and Paca, regions most heavily affected by the epidemic at present, announced the Ministry of Health. The target audiences (over 75 years old, nursing home residents, disabled people in specialized establishments, caregivers, firefighters and home helpers over 50) can now expect to be vaccinated either by one or the other. other vaccine. The differences are indeed minimal, at least in terms of technology, efficiency and side effects.
The minimal differences are due to vaccine engineering, each team having sought in its own way to make the protein produced more visible by our immune system.
Dr Nicolas Manel, virologist immunologist at Institut Curie
Like Pfizer / BioNTech, Moderna has developed a messenger RNA vaccine targeting the Spike protein located on the surface of Sars-CoV-2.
This article is for subscribers only. You have 77% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Already subscribed? Log in